Yaghoot Rooyan International Group was founded in 1991 aiming to import food supplements, pharmaceuticals, medical equipments and also herbal hygienic and cosmetic products for caring and protecting of public health and hair and skin beauty. This group has supplied the market with unique products under different commercial brands to satisfy the society requirements by its exclusive agency from more than 21 Stated manufacturers in Europe and U.S.A and now is moving forward with the precious aim of transmitting the manufacturing technology to Iran and reaching national independence. The food supplements and hygienic and cosmetic products of Yaghoot Rooyan International Group are confirmed by the expert Physicians and scientific sessions in internal international area supporting by its superior quality and performance.
Presenting different scientific articles and close co operations with experts and scholars inside and outside the country is some of the Yaghoot Rooyan International Group’s achievement’s to support researchers and promote the activities. The exterritorial activities of this group are also significant and increasing.
Subcategories
-
مقالات
- Article Count:
- 87
The American researches intend to use 3D print technology for replacement of 75% of the skull of a patient.
Three-dimensional printed implants may be used for restoration skull bone of the patients, suffering from cancer or those who are injured due a car accident.
“Scott Defelice”, Manager of Oxford Performance Materials emphasizes: “3D print technology has covered all sectors of orthopedic industry. The advantage of this technology refers to possibility for provision of scanned digital model of a patients’ skull and layer print of the said sensitive part by the help of a three-dimensional printer.
Precise 3D print method may be used for manufacture of tiny surfaces or those with subtle details including cellular replacement for joining bones.
This Company is regarded as one of the manufacturers and exporters of 3D print implants. The said Company has recently obtained respective license from Food and Drug Administration of America for implanting the first 3D print skull and it is ready to perform implanting surgery on 300-400 patients whose skull has been damaged and fractured.
Researchers are working on design and manufacture of various pieces of bones of human body using 3D print technology and performing much sensitive skull implanting surgery may establish suitable grounds for such surgery on other bones accordingly.
Researchers have recently found that it is possible to easily predict extent of violence and aggression among boys only through conducting a simple test.
In the said test, a study has been done on 17 boys of 7-9 years old and value of Testosterone and Androsterone (DHEA) hormones and that of Cortisol existing in the saliva of the said boys have been measured daily.
The results of researches have revealed that concentration of the said hormones in the sample saliva shall predict extent of violation and aggression among the said kids.
Quick and simultaneous evaluation of extent of violence among adolescences is of great importance for psychiatric and clinical treatments.
Awareness about extent of stress and study of emotional conditions of adolescences, especially during maturity period, sets a desirable model for parents and educational instructors and it causes that least hurts occur for the adolescences during said period accordingly.
پیام مدیر عامل :
ما همواره در راستای انجام مسئولیت های اجتماعی خود ضمن تلاش برای ارتقاء سلامت جامعه جهت اثبات تعهد خود به فرهنگ کیفیت و ایجاد اطمینان و افزایش رضایتمندی مشتریان و بهبود مستمر در فرآیندها تلاش می کنیم. حضور در تمام جنبه های مختلف کسب و کار دارویی ما را قادر ساخته تا محصولاتی با بالاترین کیفیت در کوتاه ترین زمان ارئه دهیم.
مفتخریم که در سایه ی ایزد منان یکی از شرکتهای دارویی به شمار می رویم که با هدف پیشگامی در تهیه و توزیع محصولات دارویی به مردم عزیزمان خدمت می کنیم.
مدیرعامل
مرتضی طهماسبی
Mr. Seyed Hosein Etemadi Monfared ,PhD,the founder of Yaghoot Rooyan Holding Group announced that the Ministry Of Health and Medical Sciences (MOH) issued the permission of principled agreement for constructing the pharmaceutical raw material manufacturing factory.
“ this permission is issued under the name of Sepid Teb Nia International Co. as one the subsets of Yaghoot Rooyan Holding group after the legal committee of assessment of Eligibility for production and import of drugs and Biologic Materials study and confirmation” Mr. Etemadi added while noting this issue.
He declared that the Supplements and Specific Foods of MOH has agreed with the pharmaceutical raw material import under the name of Nano Sepid Farmed Co. as another subsets of Yaghoot Rooyan Holding Group and added “these macro- projects based on this permission are aimed to promote the supply chain of pharmaceutical raw material and cooperate with internal and overseas industries and drug research centers emphasizing communication system with manufacturers.
Mr. Etemadi, PHD, also said that Hasti Daroo Darman international Co. as one of the Yaghoot Rooyan Holding Group also could obtain the principled agreement for establishment of co-laboratory in the field of Hygienics and cosmetics, food supplements, and specialized laboratories for hair color from technical committee of assessment and approval of allowed laboratories inside the country. So this company can observe the realization of new processes according to the last research and scientific achievements from now on.
The Yaghoot Rooyan Holding Group founder also expressed at the final part of his press conference “one of the most outstanding achievements of this Holding is obtain the permission for production of some food supplements such as Beta caroten, B12, L-citrolin,L-Ajenine and many other kinds of drugs under the name of Sepid Teb Nia International Co. from Ministry Of Health and Medical Sciences and also the permission for production special establishment, designing and assembling some of the Hygienic and cosmetic products under the name of Asal Daroo Kish International Co. from the ministry of industry, mine and commerce . we proud of all these achievements.”
New Vaccine of SAV001-H is a new version of HIV vaccine, which doesn’t have any side-effects Feature
Although researchers have tried utmost for many decays to produce AIDS vaccine, they have not been successful yet. Most of produced vaccines are not actually usable in practice due to high complications. However, now the Canadian researchers have succeeded in development of HIV vaccine, with no side-effects.
As reported by the borderless medical site reporter, it is necessary to conduct required clinical trial at several stages on the new HIV Vaccine. About five years are needed for completion of the said process and entrance of the said vaccine at consumption market.
Researchers emphasize that since the said vaccines will probably be used for treatment of patients in the next five years, therefore, confronting HIV/AIDS must still be focused on prevention using tested and real methods such as distribution of Condom, circumcising, prevention of transmission of HIV from mothers to neonates and presenting syringe exchange plans.
Every year 400-500 Million US Dollars are spent for research on HIV Vaccine. Most of the said cost is paid for basic researches.
In spite of all efforts made in this regard, specific shape of HIV has caused that finding the said vaccine will be difficult and expensive. Segregating HIV from other infectious diseases has caused that the said virus directly attacks white blood cells, which are responsible for body safety response and disables the said cells to control infection and to prevent infection with the said virus.
“Common” vaccines are based on a complete microorganism (virus or bacterium), which have been killed or inactivated. The said vaccines are not reliable for AIDS, which may lead to infection. Consequently, HIV trial vaccines contain certain parts of viruses, which make production of the said vaccine more sophisticated.
The base for production of the genetically modified vaccine is killed virus and it has entered at test stage.
This new vaccine is called “-H001SAV”.
The said virus has caused death of 30,000,000 individuals all over the world. Presently, over 34,000,000 persons are infected with the said virus.
It should be noted that presently, respective medicines used for treatment of AIDS are chemical ones, which are used as anti-virus medicines. In more than 30% cases, a patient has to replace the said medicine with another one or to change its dosage due to complications of the said medicines.
Variety in kinds of HIV has made the case more complicated. Various types of HIV virus, identified all over the world, are prevalent. Presently, researchers don’t know whether this new type of vaccine may cover the case thoroughly or it may be used for a specific kind of Virus.
The most prevalent kinds of HIV are subspecies of A and C, which exist in different regions in Africa. However, most of current reactions are done on the said kind; they cover the entire genetic aspect of subspecies B, which are dominant in countries of high incomes.
Yaghoot Rooyan International Group proudly introduce itself as one of the most reliable and active groups in marketing and supplying cosmetic and hygienic products, pharmaceutical and food supplements, prostheses from valid foreign companies and manufactures according to national standards ...
Researchers have recently found that it is possible to easily predict extent of violence and aggression among boys only through conducting a simple test.
In the said test, a study has been done on 17 boys of 7-9 years old and value of Testosterone and Androsterone (DHEA) hormones and that of Cortisol existing in the saliva of the said boys have been measured daily.
The results of researches have revealed that concentration of the said hormones in the sample saliva shall predict extent of violation and aggression among the said kids.
Quick and simultaneous evaluation of extent of violence among adolescences is of great importance for psychiatric and clinical treatments.
Awareness about extent of stress and study of emotional conditions of adolescences, especially during maturity period, sets a desirable model for parents and educational instructors and it causes that least hurts occur for the adolescences during said period accordingly.
itamin D supplementation could be a safe and cost-effective treatment strategy for individuals with multiple sclerosis, according to new research published in the journal Neurology.
Researchers found a high daily dose of vitamin D for 6 months reduced MS-related T cell activity in patients with the disease.
Numerous studies have associated low levels of vitamin D with increased risk of multiple sclerosis (MS). Additionally, among people who have MS, low vitamin D levels have been linked to greater disability and more severe symptoms.
Whether vitamin D supplementation may benefit patients with MS, however, has been a subject of debate.
With the aim of finding out, study coauthor Dr. Peter A. Calabresi, of Johns Hopkins University School of Medicine in Baltimore, MD, and colleagues analyzed the effects of vitamin D supplementation among 40 adults aged 18-55 with relapsing-remitting MS.
Each individual took either 10,400 IU (high dose) or 800 IU (low dose) of vitamin D3 supplements daily for 6 months. For comparison, the standard recommended daily vitamin D intake for adults aged 18-70 is 600 IU.
At study baseline and at 3 and 6 months, the vitamin D levels of each participant were measured through blood tests, and the researchers also assessed subjects' MS-related T cell responses - an indicator of disease activity.
High-dose vitamin D reduced MS-related T cell activity
The study results revealed that individuals who took the high dose of vitamin D3 demonstrated a reduction in the percentage of T cells associated with MS activity.
Specifically, the researchers found that when vitamin D levels in the blood reached greater than 18 nanograms per milliliter (ng/ml), each further 5 ng/ml rise in vitamin D levels was linked to a 1% fall in the percentage of interleukin-17 T cells in the blood; these cells are believed to play a role in MS pathogenesis.
No reduction in the percentage of interleukin-17 T cells in the blood was identified among individuals who took the low dose of vitamin D3.
There were no differences in side effects from vitamin D supplementation between the high-dose and low-dose groups, according to the researchers, and one person from each group experienced a disease relapse.
Though MS incidence and prevalence is not currently tracked in the US, it is estimated that around 400,000 Americans are living with the condition and around 200 new cases are diagnosed each week.
At present, there is no cure for MS; symptoms and the course of disease are normally managed through medications. But according to Dr. Calabresi, these latest findings indicate there may be a promising new treatment option for MS:
"These results are exciting, as vitamin D has the potential to be an inexpensive, safe and convenient treatment for people with MS.
More research is needed to confirm these findings with larger groups of people and to help us understand the mechanisms for these effects, but the results are promising."